Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists
This cohort study compares the risks of developing different hematologic cancers in patients with type 2 diabetes treated with glucagon-like peptide–1 receptor agonists (GLP-1RAs) compared with metformin and insulin.
Authors
- Faiz Anwer (ORCID: https://orcid.org/0000-0001-6914-7439)
- Omer S. Ashruf (ORCID: https://orcid.org/0000-0003-1385-0090)
- Jasmin Hundal (ORCID: https://orcid.org/0000-0002-1358-1209)
- Abhay Singh (ORCID: https://orcid.org/0000-0001-6657-8647)
- David C. Kaelber (ORCID: https://orcid.org/0000-0001-7855-9515)
- Ali Mushtaq (ORCID: https://orcid.org/0000-0003-1939-1665)
Institutions
- MetroHealth (US)
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Case Western Reserve University (US)
- Northeast Ohio Medical University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.0802
- Citations
- 12
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 9.67
Funders
- National Institutes of Health
- Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University
- National Center for Advancing Translational Sciences